Trade
Lupin share price
Moderate risk
You have to be logged in to add this to Watchlist.- ₹2,496.70(-0.04%)July 14, 2026 12:20:08 PM IST
- NSE
- BSE
- Vol : 176.71 K (NSE + BSE)Last 20 day avg : 847.90 K
Lupin is trading -0.04% lower at Rs 2,496.70 as compared to its last closing price. Lupin has been trading in the price range of 2,508.00 & 2,484.55. Lupin has given 18.16% in this year & 0.04% in the last 5 days. Lupin has TTM P/E ratio 18.66 as compared to the sector P/E of 26.11.There are 36 analysts who have initiated coverage on Lupin. There are 6 analysts who have given it a strong buy rating & 10 analysts have given it a buy rating. 4 analysts have given the stock a sell rating.The company posted a net profit of 1,460.34 Crores in its last quarter.Listed peers of Lupin include Torrent Pharmaceuticals (1.13%), Dr Reddy's Laboratories (0.79%), Cipla (1.87%).The Mutual Fund holding in Lupin was at 16.93% in 31 Mar 2026. The MF holding has decreased from the last quarter. The FII holding in Lupin was at 21.70% in 31 Mar 2026. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Key Metrics
Updated on Jul 14, 2026, 06:51 AM UTC
- BetaLow volatility0.52Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.29The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.72Annual dividends as a percentage of the stock price.
- PEG RatioIndicates undervaluation0.15The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Lupin News
Lupin Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Torrent Pharmaceuticals | 5,003.80 | 1.13 | 1,69,344.53 | 67.32 | 17.1 | 0.83 | 17.62 |
| Dr Reddy's Laboratories | 1,244.40 | 0.79 | 1,03,862.19 | 18.63 | 3.14 | 0.63 | 2.34 |
| Cipla | 1,453.50 | 1.87 | 1,17,362.74 | 22.95 | 3.87 | 0.87 | 0.81 |
| Sun Pharmaceutical Industries | 1,945.75 | 1.13 | 4,66,839.60 | 36.24 | 5.77 | 0.92 | 0.50 |
| Divi's Laboratories | 7,120.95 | 2.71 | 1,89,249.03 | 78.61 | 11.52 | 0.46 | 0.01 |
Mutual Fund Ownership
View allLupin Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-05-07 | Audited Results & Final Dividend |
| 2026-02-12 | Quarterly Results |
| 2025-11-06 | Quarterly Results & Others |
| 2025-08-05 | Quarterly Results & Others |
| 2025-05-14 | Audited Results & Final Dividend |
About the company Lupin
- IndustryBiotechnology & Drugs
- ISININE326A01037
- BSE Code500257
- NSE CodeLUPIN
Lupin Limited is a global pharmaceutical company, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It operates in India and the United States across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. It has a presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastro-Intestinal, Anti-Infectives and Nonsteroidal Anti-Inflammatory Drug therapy segments and operates in the Anti-TB and Cephalosporins segments. Its generic formulations include Filgrastim, Peg filgrastim, Etanercept and Albuterol. Its diabetes brands include Gibtulio, Ajaduo, Gibtulio Met, ONDERO and ONDERO MET. Its other brands include AntaGolin, RyChol and others. Its Huminsulin range of products includes Insulin Human.
Lupin Share Price FAQs
Lupin is trading at 2496.70 as on Tue Jul 14 2026 06:50:08. This is -0.04% lower as compared to its previous closing price of 2497.75.
The market capitalization of Lupin is 114742.97 Cr as on Tue Jul 14 2026 06:50:08.
The average broker rating on Lupin is Hold. The breakup of analyst rating is given below -
- 6 analysts have given a strong buy rating
- 10 analysts have given a buy rating
- 13 analysts have given a hold rating
- 4 analysts have given a sell rating
- 3 analysts have given a strong sell rating
The 52 wk high for Lupin is 2526.00 whereas the 52 wk low is 1838.65
Lupin can be analyzed on the following key metrics -
- TTM P/E: 18.66
- Sector P/E: 26.11
- Dividend Yield: 0.72%
- D/E ratio: 0.29
Lupin reported a net profit of 5332.84 Cr in 2026.
The Mutual Fund Shareholding was 16.93% at the end of 31 Mar 2026.
Quick Links
EQUITY QUICK LINKS
Lupin QUICK LINKS
FROM MARKETS
RELATED LINKS
Quarterly Results
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.